OHR Pharmaceutical Inc (OHRP) was Resumed by ROTH Capital to “Buy” and the brokerage firm has set the Price Target at $13. ROTH Capital advised their investors in a research report released on Jun 16, 2016.
OHR Pharmaceutical Inc closed down -0.07 points or -2.47% at $2.76 with 2,27,347 shares getting traded on Wednesday. Post opening the session at $2.82, the shares hit an intraday low of $2.69 and an intraday high of $2.85 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on May 26, 2016, Jason Scott Slakter (CEO) purchased 3,682 shares at $3.12 per share price. According to the SEC, on May 24, 2016, Samuel Backenroth (CFO) purchased 2,500 shares at $3.17 per share price. On Feb 10, 2015, Irach B. Taraporewala (CEO) purchased 3,705 shares at $6.75 per share price, according to the Form-4 filing with the securities and exchange commission.
Ohr Pharmaceutical Inc. is a pharmaceutical company. The Company is focusing on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of various programs and indications at various stages of development. The Company’s clinical program OHR-102 eye drops is a therapeutic product that provides a non-invasive therapy to improve vision outcomes without requiring multiple injections per office visit. The Company focuses on OHR-102 eye drops which is given in combination with Lucentis injections for the treatment of retinal diseases including wet-age-related macular degeneration (AMD) retinal vein occlusion and proliferative diabetic retinopathy. The Company’s product pipeline also includes SKS Sustained Release Ocular Drug Delivery Platform Technology Animal Model for Dry-AMD and Non-Ophthalmology Assets. OHR-102 is a small molecule anti-angiogenic drug with an intracellular mechanism of action.